Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Innate Pharma is a biotechnology business based in the US. Innate Pharma shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars. Innate Pharma employs 213 staff and has a trailing 12-month revenue of around $57 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $3.45 |
|---|---|
| 52-week range | $1.90 - $4.10 |
| 50-day moving average | $2.77 |
| 200-day moving average | $2.68 |
| Wall St. target price | $8.06 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.69 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.45 from 2023-01-27
| 1 week (2023-01-23) | -1.71% |
|---|---|
| 1 month (2022-12-30) | -7.51% |
| 3 months (2022-10-28) | 60.47% |
| 6 months (2022-07-29) | 7.81% |
| 1 year (2022-01-28) | -3.90% |
|---|---|
| 2 years (2021-01-29) | -15.65% |
| 3 years (2020-01-30) | 6.9 |
| 5 years (2018-01-26) | N/A |
| Revenue TTM | $57 million |
|---|---|
| Gross profit TTM | $-22,301,000 |
| Return on assets TTM | -4.3% |
| Return on equity TTM | -17.31% |
| Profit margin | -39.99% |
| Book value | $1.46 |
| Market capitalisation | $302.8 million |
TTM: trailing 12 months
We're not expecting Innate Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Innate Pharma's shares have ranged in value from as little as $1.9 up to $4.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma's is 0.3569. This would suggest that Innate Pharma's shares are less volatile than average (for this exchange).
Innate Pharma S. A. , a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S. A.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
